Biocon Pharma Ltd, a subsidiary of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for its generic version of Everolimus tablets. These tablets are used to treat specific conditions associated with Tuberous Sclerosis Complex (TSC), including non-cancerous tumors and partial-onset seizures in patients aged one year and above. The approval, granted for 2 mg, 3 mg, and 5 mg strengths, is expected to enhance Biocon's drug product portfolio.